Adela Ramirez-Torres, PhD, earned her bachelor’s degree in biology from the Universidad Autonoma de Madrid, and doctorate from Universidad de Zaragoza in Spain. After completing her doctorate, she became a project scientist at Mosaiques Diagnostics GmbH in Germany, where she effectively developed new panels of peptide-based biomarkers for various human diseases. In 2015, Ramirez-Torres was sponsored by Sanford Burnham Prebys Medical Discovery Institute, an NCI-Designated Cancer Center, in La Jolla. Her work focused on the study of post-translational modifications occurring to the oncogene HIF-2 and its aggressiveness in renal clear cell carcinoma patients, with pVHL loss. In 2017, she became part of the Freedland Laboratory. She is leading in vitro and in vivo studies to discover the role CYP27A1 gene and its metabolite, 27-hydroxycholesterol, as a potential tumor suppressor and treatment, respectively, during prostate carcinogenesis.